← Leaderboards
Susan Lanza-Jacoby
Thomas Jefferson University
$1,485,396
Attributed
$1,485,396
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $232.5K · FY2005–16$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$1,485,396 · 5
By mechanism
R21$1,171,396 · 3
R03$314,000 · 2
Top collaborators
No co-investigators on record.
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Edward R Sauter$2,422,584
- Jonathan Brody$5,162,616
- David Timothy Hoang$132,227
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseApoptosisLesionTransgenic MiceBaseMouse ModelNih Program AnnouncementsTumorGrowthIncidenceBiomarkerAnimal ModelMalignant Breast NeoplasmLifeLaboratory MouseLeadMalignant Neoplasm Of PancreasHuman Frap1 ProteinFeedingInhibitor/AntagonistMalignant NeoplasmsDiagnosisCell DeathInsulin
Grant awards (10)
A new energy restriction mimetic that targets pancreatic cancer$169,650
R21 · FY2016 · CA · contact PI
A new energy restriction mimetic that targets pancreatic cancer$203,580
R21 · FY2015 · CA · contact PI
Breast cancer prevention with Nexrutine$191,813
R21 · FY2012 · AT · contact PI
Breast cancer prevention with Nexrutine$232,463
R21 · FY2011 · AT · contact PI
Variations of calorie restriction for the prevention of pancreatic cancer$169,950
R21 · FY2010 · CA · contact PI
Variations of calorie restriction for the prevention of pancreatic cancer$203,940
R21 · FY2009 · CA · contact PI
Breast cancer prevention with COX-2 and EGFR inhibitors$78,500
R03 · FY2005 · CA
Breast cancer prevention with COX-2 and EGFR inhibitors$78,500
R03 · FY2004 · CA
Cyclooxygenase-2 Inhibition, Angiogenesis, Breast Cancer$78,500
R03 · FY2003 · CA
Cyclooxygenase-2 Inhibition, Angiogenesis, Breast Cancer$78,500
R03 · FY2002 · CA